Mineralys Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Mineralys Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2022 to Q3 2024.
  • Mineralys Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $3.14M, a 98.9% increase year-over-year.
  • Mineralys Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $9.66M, a 153% increase year-over-year.
  • Mineralys Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5.06M, a 1012% increase from 2022.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $9.66M $3.14M +$1.56M +98.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $8.1M $2.87M +$1.6M +125% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $6.5M $2.19M +$1.44M +193% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $5.06M $1.46M +$1.24M +568% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 $3.82M $1.58M +$1.39M +722% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $2.44M $1.28M +$1.25M +4808% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $1.19M $749K +$730K +3842% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $455K $218K Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 $192K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $26K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $19K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.